| Basics |
Biogen Inc.
Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$25.54B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$2.46 | 1.33%
|
| Avg Daily Range (30 D): |
$2.20 | 1.31%
|
| Avg Daily Range (90 D): |
$2.24 | 1.49%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
2.07M |
| Avg Daily Volume (30 D): |
1.58M |
| Avg Daily Volume (90 D): |
1.39M |
| Trade Size |
| Avg Trade Size (Sh.): |
106 |
| Avg Trade Size (Sh.) (30 D): |
43 |
| Avg Trade Size (Sh.) (90 D): |
41 |
| Institutional Trades |
| Total Inst.Trades: |
44,463 |
| Avg Inst. Trade: |
$6.08M |
| Avg Inst. Trade (30 D): |
$12.56M |
| Avg Inst. Trade (90 D): |
$11.28M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
8 |
| Market Closing Trades |
| Avg Closing Trade: |
$28.01M |
| Avg Closing Trade (30 D): |
$49.88M |
| Avg Closing Trade (90 D): |
$40.61M |
| Avg Closing Volume: |
136.31K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$3.18
|
$4.33
|
|
Diluted EPS
|
|
$3.17
|
$4.33
|
|
Revenue
|
$
|
$ 2.53B
|
$ 2.65B
|
|
Gross Profit
|
$
|
$ 1.86B
|
$ 2.04B
|
|
Net Income / Loss
|
$
|
$ 466.5M
|
$ 634.8M
|
|
Operating Income / Loss
|
$
|
$ 557.3M
|
$ 744M
|
|
Cost of Revenue
|
$
|
$ 674.4M
|
$ 605M
|
|
Net Cash Flow
|
$
|
$ 1.1B
|
$ 160.5M
|
|
PE Ratio
|
|
|
|
|
|
|
